Flurazepam (Dalmane) and Desalkylflurazepam
Use
This test provides quantitative analysis of flurazepam (Dalmane) and its metabolite, desalkylflurazepam, in plasma or serum. This can assist clinicians in monitoring therapeutic dosing, compliance, and assessing possible toxicity associated with flurazepam use. The test offers valuable data in clinical scenarios where benzodiazepine levels need precise measurement for effective therapeutic intervention.
Special Instructions
Routine venipuncture with detailed handling of specimens is critical. Avoid using gel tubes for collection, as components can interfere with testing. The specimens must be frozen prior to transport to ensure stability. Communicate any special handling needs or coordination for specimens sent from New York state as this test is approved for NY State clients.
Limitations
The test cannot differentiate between levels from freshly administered flurazepam versus levels from drug accumulation. External factors such as co-administration of other drugs may affect flurazepam and desalkylflurazepam levels in unpredictable ways. Specimen integrity is crucial; improper handling and storage of samples may lead to inaccurate results. Hemolysis, lipemia, or icterus do not invalidate the sample but may affect results.
New York Approved
Methodology
Mass Spectrometry (LC-MS/MS)
Biomarkers
LOINC Codes
- 73826-0
- 46979-1
- 46980-9
- 73826-0
Result Turnaround Time
5-9 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
2 mL
Minimum Volume
0.3 mL
Container
Green-top (sodium heparin) tube; plasma gel tube unacceptable.
Collection Instructions
Draw blood in a green-top (sodium heparin) tube(s), spin down and send 2 mL sodium heparin plasma frozen in plastic vial.
Storage Instructions
Send frozen in plastic vial.
Causes for Rejection
NA
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 180 days |